Clinical testing for molecular targets for personalized treatment in lung cancer.

摘要: Lung cancer is the leading cause of mortality worldwide. Over past decades, management advanced stage lung has been revolutionized from very limited options systemic chemotherapy with efficacy to present testing for biomarkers (epidermal growth factor receptor (EGFR), gene mutations) guide therapeutic decision and improve treatment. Relevant advancement in understanding biology also revealed that different tumours may carry driver mutations thus adopt carcinogenic pathways. These were found be mutually exclusive individual tumour further supporting rationale sample presence these mutations, especially when there could corresponding specific agents against molecular targets. The aim this article review current targets are important personalized therapy how targets, namely EGFR, KRAS ALK, will cancer.